Grifols, a global healthcare company and manufacturer of plasma-derived medicines, has established a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to test investigational ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sulfur mustard exposure. BARDA is part of the U.S. Department of Health and Human Services (HHS).   If the preclinical evaluation is successful, the U.S. FDA could eventually license what would be...